Investment analysts at SunTrust initiated coverage on shares of Amarin Co. plc (NASDAQ:AMRN) in a note issued to investors on Wednesday, TheFlyOnTheWall.com reports. The firm set a “buy” rating on the stock.
AMRN has been the subject of a number of other recent research reports. Analysts at Citigroup Inc. reiterated a “buy” rating on shares of Amarin Co. plc (NASDAQ:AMRN) in a research note to investors on Monday, August 12th. They now have a $11.00 price target on the stock, down previously from $13.00. Separately, analysts at MKM Partners cut their price target on shares of Amarin Co. plc (NASDAQ:AMRN) from $12.00 to $9.00 in a research note to investors on Friday, August 9th. They now have a “buy” rating on the stock. Finally, analysts at Canaccord Genuity cut their price target on shares of Amarin Co. plc (NASDAQ:AMRN) from $17.00 to $10.00 in a research note to investors on Friday, August 9th. They now have a “buy” rating on the stock.
Two analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. Amarin Co. plc has an average rating of “Buy” and an average price target of $12.14.
Amarin Co. plc (NASDAQ:AMRN) opened at 6.31 on Wednesday. Amarin Co. plc has a 1-year low of $5.12 and a 1-year high of $14.97. The stock has a 50-day moving average of $5.68 and a 200-day moving average of $6.73. The company’s market cap is $1.089 billion.
Amarin Co. plc (NASDAQ:AMRN) last announced its earnings results on Thursday, August 8th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.38) by $0.12. The company had revenue of $5.50 million for the quarter. Analysts expect that Amarin Co. plc will post $-1.36 EPS for the current fiscal year.
Amarin Corporation plc (NASDAQ:AMRN) is a late-stage biopharmaceutical -company with expertise in lipid science focused on the treatment of cardiovascular disease.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.